These results suggest that the inhibition of CDK4/6 in combination with ET pushes breast cancer cells toward an alternative FGF signaling dependence to sustain cellular proliferation via a CDK4/6- and endocrine-independent mechanism. Here, CDK4 is linked to breast cancer.